Repligen Corporation (RGEN) - Total Assets
Based on the latest financial reports, Repligen Corporation (RGEN) holds total assets worth $2.95 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Repligen Corporation - Total Assets Trend (1985–2025)
This chart illustrates how Repligen Corporation's total assets have evolved over time, based on quarterly financial data. Also see Repligen Corporation stock valuation for the company's overall valuation and market capitalisation.
Repligen Corporation - Asset Composition Analysis
Current Asset Composition (December 2025)
Repligen Corporation's total assets of $2.95 Billion consist of 38.6% current assets and 61.4% non-current assets. Review Repligen Corporation total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.2% |
| Accounts Receivable | $158.59 Million | 5.4% |
| Inventory | $170.46 Million | 5.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $386.15 Million | 13.1% |
| Goodwill | $1.11 Billion | 37.8% |
Asset Composition Trend (1985–2025)
This chart illustrates how Repligen Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See today's stock price for Repligen Corporation for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Repligen Corporation's current assets represent 38.6% of total assets in 2025, a decrease from 68.9% in 1985.
- Cash Position: Cash and equivalents constituted 19.2% of total assets in 2025, down from 61.2% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is goodwill at 37.8% of total assets.
Repligen Corporation Competitors by Total Assets
Key competitors of Repligen Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Shenyang Xingqi Pharmaceutical Co Ltd
SHE:300573
|
China | CN¥2.42 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Embecta Corp
NASDAQ:EMBC
|
USA | $1.27 Billion |
Repligen Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.05 | 8.59 | 2.61 |
| Quick Ratio | 7.64 | 7.32 | 2.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.07 Billion | $933.85 Million | $561.41 Million |
Repligen Corporation - Advanced Valuation Insights
This section examines the relationship between Repligen Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.50 |
| Latest Market Cap to Assets Ratio | 3.16 |
| Asset Growth Rate (YoY) | 4.2% |
| Total Assets | $2.95 Billion |
| Market Capitalization | $9.31 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Repligen Corporation's assets at a significant premium (3.16x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Repligen Corporation's assets grew by 4.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Repligen Corporation (1985–2025)
The table below shows the annual total assets of Repligen Corporation from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.95 Billion | +4.24% |
| 2024-12-31 | $2.83 Billion | +0.19% |
| 2023-12-31 | $2.82 Billion | +11.57% |
| 2022-12-31 | $2.53 Billion | +7.35% |
| 2021-12-31 | $2.36 Billion | +23.94% |
| 2020-12-31 | $1.90 Billion | +35.91% |
| 2019-12-31 | $1.40 Billion | +904.03% |
| 2018-12-31 | $139.45 Million | +15.81% |
| 2017-12-31 | $120.41 Million | -58.32% |
| 2016-12-31 | $288.91 Million | +97.56% |
| 2015-12-31 | $146.24 Million | -323.52% |
| 2014-12-31 | $-65.43 Million | -155.14% |
| 2013-12-31 | $118.64 Million | +22.30% |
| 2012-12-31 | $97.01 Million | +27.48% |
| 2011-12-31 | $76.10 Million | +5.26% |
| 2010-12-31 | $72.29 Million | +1.22% |
| 2009-12-31 | $71.42 Million | -3.17% |
| 2008-12-31 | $73.75 Million | +7.14% |
| 2007-12-31 | $68.84 Million | +136.76% |
| 2006-12-31 | $29.08 Million | +1.67% |
| 2005-12-31 | $28.60 Million | +3.59% |
| 2004-12-31 | $27.61 Million | -6.78% |
| 2003-12-31 | $29.61 Million | -10.66% |
| 2002-12-31 | $33.15 Million | +13.87% |
| 2001-12-31 | $29.11 Million | -9.45% |
| 2000-12-31 | $32.15 Million | -11.41% |
| 1999-12-31 | $36.29 Million | +597.84% |
| 1998-12-31 | $5.20 Million | -8.77% |
| 1997-12-31 | $5.70 Million | -14.93% |
| 1996-12-31 | $6.70 Million | +17.54% |
| 1995-12-31 | $5.70 Million | -81.79% |
| 1994-12-31 | $31.30 Million | -23.84% |
| 1993-12-31 | $41.10 Million | -13.29% |
| 1992-12-31 | $47.40 Million | -19.66% |
| 1991-12-31 | $59.00 Million | +8.86% |
| 1990-12-31 | $54.20 Million | +43.39% |
| 1989-12-31 | $37.80 Million | +53.04% |
| 1988-12-31 | $24.70 Million | -10.18% |
| 1987-12-31 | $27.50 Million | +19.57% |
| 1986-12-31 | $23.00 Million | +123.30% |
| 1985-12-31 | $10.30 Million | -- |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, … Read more